Poster Presentation at the Annual Meeting of The Society of Nuclear Medicine, Salt Lake City, UT, June 6-9, 2010. Shah R, Borghei P, Patel B, Palmer C, Cure J. Utility of serial lesion quotient ...

SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies ...

MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced three poster presentations at the 2025 American ...

Throughout the series, attendees can expect in-depth discussions and presentations on the latest developments ... rare disease personalized care Immunotherapy and precision medicine Call for Posters — ...

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP ...

Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE ...